Tarceva Pancreatic Cancer Data Do Not Support Broad Use – ASCO Review
Executive Summary
Results from Genentech/OSI's Phase III trial of Tarceva (erlotinib) in advanced pancreatic cancer do not support broad use, according to a review at the American Society of Clinical Oncology annual meeting